A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review

January 12 2022

We are happy to report that the Protocol Development Department coordinated the activation of 10 studies: 8 through CTEP and 2 through DCP over a broad number of disease sites (See table).The exciting news is that we have another 11 NCI approved concepts along with 3 NCI ComboMATCH studies that are in protocol development with activations anticipated in 2022/2023. There are 19 other concepts that were approved for future development during our Research Strategy Meetings held this past year. A list of new protocols under development is included in each monthly NRG Oncology newsletter. We are thankful to have a robust and diverse clinical trial portfolio and are excited about the new trial concepts we continue to receive from our dedicated committees and investigators.

On behalf of NRG Oncology’s Research Strategy Committee’s leadership, we want to thank our study chairs, committee leaders and members, and our amazing staff for all their hard work and resulting success this past year.We look forward to an even better 2022!

Ronald D. Alvarez, MD

Jame Abraham, MD



Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.